UNSPSC 51281640: Capreomycin ib

This classification denotes an antitubercular agent and aminoglycoside antibiotic with the molecular formula C25H44N14O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2YP3RYC823, chemically known as cyclo((2s)-2-amino-.beta.-alanyl-l-alanyl-3-(((3s)-3,6-diamino-1-oxohexyl)amino)-l-alanyl-(2z)-3-((aminocarbonyl)amino)-2,3-didehydroalanyl-(2s)-2-((4r)-2-amino-3,4,5,6-tetrahydro-4-pyrimidinyl)glycyl), but more generally known as capreomycin ib, which bears US NIH Compound Identifier 3034057.

UNSPSC 51281640 Capreomycin ib is a Commodity code, but state and local procurement activity under this code shows minimal alignment with the actual pharmaceutical listed. Recent opportunities posted under this code do not reflect capreomycin procurement; instead, they document solicitations for naloxone, safe drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals through cooperative purchasing vehicles. The code appears to represent a cataloging mismatch rather than an active procurement category for the specific antibiotic product named.

The geographic spread of recent activity spans Florida (Seminole County), Texas (HHS Commission), and Minnesota (MMCAP cooperative purchasing serving multiple state and local jurisdictions including Oregon). Issuing bodies include county health departments, state HHS agencies, municipal fire departments, and cooperative purchasing alliances. The most recent opportunities are the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products posted January 20, 2026 with a March 26, 2026 response deadline; the City of Tampa IFB 26-P-00145 for medical and first aid supplies for the Fire Department Rescue Division, posted March 25, 2026 with a March 13, 2026 deadline and an estimated contract value of $700,000; Seminole County's IFB 60459723LAS for naloxone and drug deactivation systems, posted June 30, 2026 with a July 26, 2023 deadline; and the Texas HHS Commission RFI HHS0017013 for direct-to-manufacturer prescription programs, posted April 3, 2026. The code does not track capreomycin-specific procurement activity in the recent state and local market.